Andrew Huberman· PhD
I think the evidence is strong enough that I take it / recommend it.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
I think the evidence is strong enough that I take it / recommend it.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
I think the evidence is strong enough that I take it / recommend it.
I think the evidence is strong enough that I take it / recommend it.
Rapamycin extends median lifespan in late-life mice across multiple lab sites.
Companion ITP analysis used to validate rapamycin's replicability across NIA test sites.
Canonical reference on the mTOR pathway — the mechanistic backbone for the rapamycin longevity hypothesis.
The original human trial showing improved vaccine response in older adults on RAD001.
Weekly rapamycin shows acceptable safety in healthy adults over 48 weeks. Effect on aging markers preliminary.
Lifespan extension is consistently larger in females than males — a robust replicated finding.
Late-life initiation still works — the timing window is wider than first assumed.
Argues the cancer-prevention signal is one of the most robust effects of mTORC1 inhibition.
Argues low-dose rapamycin protocols circulating online run ahead of immune-safety surveillance; flags infection-risk windows.
Reversal (not just slowing) of age-related cardiac dysfunction in old mice.
Glucose-handling side effects are dose-dependent and partially decoupled from the longevity mechanism.
Transplant-population data on infection risk — not directly transferable to healthy adults but the most-quoted reference point.
Counterintuitive wound-healing findings depending on route and dose — used to debate the surgical-pause guidance.
No mortality benefit observed in a small self-selected cohort. Severe confounders; underpowered.
Editorial framing of the social-media rapamycin protocols as outpacing the safety surveillance.
For healthy adults at standard weekly doses: Partially Supported. For those with kidney issues or active infection: not without a physician.
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.